梅毒与梅毒合并病毒性肝炎患者外周血T淋巴细胞亚群变化*

doi:10.3969/j.issn.1672-5069.2022.01.009

Abstract

Abstract: Objective The aim of this study was to investigate the clinical implication of peripheral blood T lymphocyte subset changes in patients with syphilis and hepatitis B or hepatitis C coinfection. Methods 93 patients with treponema pallidum (TP) syphilis were admitted to our hospital between January 2016 and June 2020, including syphilis infection in 61 cases, syphilis with hepatitis B virus infection in 21 cases and syphilis with hepatitis C virus infection in 11 cases. 84 healthy persons were selected as the control. The peripheral blood T lymphocyte subsets was assayed by FCM. Results The percentages of peripheral blood CD3⁺, CD4⁺, CD4⁺CD45RO⁺ and CD8⁺CD45RA⁺ cells as well as the ratio of CD4⁺/CD8⁺ cells in patients with syphilis were(52.2±8.5)%,(40.3±5.7)%,(18.1±3.9)%, (12.4±3.7)% and (1.2±0.3), all significantly lower than [(69.1±7.6)%,(50.7±6.9)%,(20.6±4.7)%,(16.2±4.3)% and (1.9±0.5), respectively, P＜0.05], while the percentages of peripheral blood CD8⁺, CD4⁺CD45RA⁺and CD8⁺CD45RO⁺ cells were all significantly higher than those in healthy control [(32.4±7.3)%, (24.7±6.5)% and (8.7±1.5)% vs. (26.2±5.4)%, (21.8±6.2)% and (5.4±1.1)%, respectively, P＜0.05]; there were significant differences as respect to the percentages of peripheral blood CD8⁺, CD4⁺CD45RA⁺, CD4⁺CD45RO⁺, CD8⁺CD45RA⁺, CD8⁺CD45RO⁺ cells and the ratio of CD4⁺/CD8⁺ cells among patients with TP, with TP and chronic hepatitis B (CHB), and with TP and chronic hepatitis C (CHC, P＜0.05), the percentages of CD8⁺, CD4⁺CD45RA⁺ and CD8⁺CD45RO⁺ cells in patients with TP and CHB and patients with TP and CHC were all significantly higher than those in patients with TP(P＜0.05), while the ratio of CD4⁺/CD8⁺ cells, and the percentages of blood CD4⁺CD45RO⁺ and CD8⁺CD45RA⁺ cells were all significantly lower than those in patients with TP (P＜0.05); there were no significant differences respect to the percentage of blood CD8⁺, CD4⁺CD45RA⁺, CD4⁺CD45RO⁺, CD8⁺CD45RA⁺ and CD8⁺CD45RO⁺ cells and the ratio of CD4⁺/CD8⁺ cells between patients with TP and CHB, and those with TP and CHC (P＞0.05). Conclusion The percentages of peripheral blood CD3⁺, CD4⁺, CD8⁺, CD4⁺CD45RA⁺, CD8⁺CD45RO⁺, CD4⁺CD45RO⁺, CD8⁺CD45RA⁺ and the ratio of CD4⁺/CD8⁺ cells in patients with TP change greatly, and those in patients with TP and HBV or HCV mixed infection change even significantly, which needs further clinical investigation.

Key words: Syphilis, Hepatitis B, Hepatitis C, T lymphocytes, Mixed infection

Qu Xiaowei, Feng Lili, Mao Yanyun. Clinical implication of peripheral blood T lymphocyte subset changes in patients with syphilis and hepatitis B or hepatitis C coinfection[J]. Journal of Practical Hepatology, 2022, 25(1): 34-37.

References

[1] Enríquez-Ruano P, Navarro CE, Ariza-Varón M, et al. Myelopathy secondary to human T-lymphotropic virus and treponema pallidum infection: case report. Spinal Cord Ser Cases, 2019, 5(12):93-97.
[2] Guo N, Liu L, Yang X, et al. Immunological changes in monocyte subsets and their association with foxp3⁺ regulatory T cells in HIV-1-infected individuals with syphilis: a brief research report. Front Immunol, 2019, 10(6):714-721.
[3] Kenyon C, Osbak KK, Crucitti T, et al. Syphilis reinfection is associated with an attenuated immune profile in the same individual: a prospective observational cohort study. BMC Infect Dis, 2018, 18(1):479-485.
[4] Jary A, Dienta S, Leducq V, et al. Seroprevalence and risk factors for HIV, HCV, HBV and syphilis among blood donors in Mali. BMC Infect Dis, 2019, 19(1):1064-1073.
[5] Oliveira D, Martins MDR, Castro R, et al. HIV, HBV and syphilis screening in antenatal care in Lubango, Angola. Sex Transm Infect, 2020, 96(8):621-622.
[6] Yang T, Chen Q, Li D, et al. High prevalence of syphilis, HBV, and HCV co-infection, and low rate of effective vaccination against hepatitis B in HIV-infected patients in West China hospital. J Med Virol, 2018, 90(1):101-108.
[7] 安哲, 王香玲. 2014版欧洲梅毒管理指南(实验室诊断部分). 现代检验医学杂志, 2016, 31(4):162-164.
[8] 樊尚荣, 梁丽芬. 2015年美国疾病控制中心性传播疾病诊断和治疗指南(续)-梅毒的诊断和治疗指南. 中国全科医学, 2015, 12(27):9-13.
[9] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32.
[10] 中华医学会肝病学分会和感染病学分会.《丙型肝炎防治指南》2019年更新版.实用肝脏病杂志,2020,23(1):S33-52.
[11] Tampa M, Sarbu I, Matei C, et al. Brief history of syphilis. J Med Life, 2014, 7(1):4-10.
[12] Arando Lasagabaster M, Otero Guerra L. Syphilis. Enferm Infecc Microbiol Clin, 2019, 37(6):398-404.
[13] Bastos FI, Bastos LS, Coutinho C, et al. HIV, HCV, HBV, and syphilis among transgender women from Brazil: Assessing different methods to adjust infection rates of a hard-to-reach, sparse population. Medicine, 2018,97(1):S16-S24.
[14] Oliveira D, Martins MDR, Castro R, et al. Seropositivity rate and sociodemographic factors associated to HIV, HBV, HCV and syphilis among parturients from Irene Neto Maternity of Lubango city, Angola. Sex Transm Infect, 2020, 96(8):587-589.
[15] 刘春国, 邵嘉佳, 王凌, 等. 性病梅毒患者实施外周血检验的应用价值. 中国性科学, 2019, 232(5):146-148.
[16] 余快, 银林, 何流. 不同分期梅毒患者外周血中T细胞亚群表达差异及价值. 中国性科学, 2019, 237(10):115-118.
[17] Nicolini LA, Orsi A, Tatarelli P, et al. A global view to HBV chronic infection: Evolving strategies for diagnosis, treatment and prevention in immunocompetent individuals. Int J Environ Res Public Health, 2019, 16(18):3307.
[18] Gentile G, Antonelli G. HBV reactivation in patients undergoing hematopoietic stem cell transplantation: A narrative review. Viruses, 2019, 11(11):1049.
[19] Li F, Wang Z, Hu F, et al. Cell culture models and animal models for HBV study. Adv Exp Med Biol, 2020, 1179(8):109-135.
[20] Vlachogiannakos J, Papatheodoridis GV. Hepatitis B: who and when to treat. Liver Int, 2018, 12(5):71-78.
[21] Heim K, Neumann-Haefelin C, Thimme R, et al. Heterogeneity of HBV-specific CD8⁺ T-Cell failure: implications for immunotherapy. Front Immunol, 2019, 10(4):2240.

Clinical implication of peripheral blood T lymphocyte subset changes in patients with syphilis and hepatitis B or hepatitis C coinfection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liu Wenzhu, Hu Xin, Jiang Wei, et al. Small ubiquitin-like modifier specific protease 3 promotes hepatitis C virus replication by regulating lipid droplets levels in HepG2 cells in vitro [J]. Journal of Practical Hepatology, 2022, 25(2): 161-164.
[2]	Yang Yan, Liu Ting, Dai Lin, et al. Noninvasive assessment of liver fibrosis via liver and spleen stiffness measurement using acoustic palpation elastography in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(2): 183-186.
[3]	Huang Ping, Zeng Xia, Zhang Yaping, et al. Evaluation of significant liver fibrosis by hepatic vein waveform classification and ultrasound-based semi-quantitative scoring in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(2): 187-190.
[4]	Li Zhen, Ning Shanshan, Guo Ying, et al. Hepatic expression of liver X receptorα and cytochrome P450 isoform 7A1 in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(2): 191-194.
[5]	Sun Jieqi, Jiang Shaowen, Wang Zheng. Comparison of virologic response to elbavir/glarevir therapy innaïve and re-treated patients with chronic hepatitis C with HCV genotype 1b infection [J]. Journal of Practical Hepatology, 2022, 25(2): 195-198.
[6]	Hao Yuting, Lin Jie, Qin Jie. Clinical implication of serum aquaporin-8 and aquaporin-9 in patients with hepatitis B-induced liver cirrhosis receiving long-term entecavir therapy [J]. Journal of Practical Hepatology, 2022, 25(2): 243-246.
[7]	Liu Huimin, Liu Xiaoli, Wang Xinhui, et al. Implication of peripheral CD4+T, CD8+T, Tc17, Th17 and Treg lymphocyte changes in patients with primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(2): 255-258.
[8]	Chen Weibing, Wang Xiaohong, Liu Fang. Effects of core proteins of different quasispecies of genotype 1b hepatitis C virus on biological behaviors of HepG2 cells in vitro [J]. Journal of Practical Hepatology, 2022, 25(1): 13-16.
[9]	Yan Jingquan, Wang Chunling, Liu Juan, et al. Predictive value of antiviral response by serum hepatitis B virus pregenomic RNA levels in naïve patients with hepatitis B receiving nucleos(t)ide analogues treatment [J]. Journal of Practical Hepatology, 2022, 25(1): 22-25.
[10]	Zheng Shuying, Guo Huanhuan, Cheng Changhao, et al. Treatment with sofosbuvir and ledipasvir for three months without ribavirin in patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2022, 25(1): 26-29.
[11]	Bao Feiyun, Li Tong, Wang Yushan, et al. Real-world study of efficacy and safety of sofosbuvir/velpatasvir in treatment of patients with hepatitis C and hepatitis C precipitated liver cirrhosis in a single centre of western-north China [J]. Journal of Practical Hepatology, 2022, 25(1): 30-33.
[12]	Expert Group for Project of Hepatocellular Carcinoma Screening and Surveillance, Chinese Foundation for Hepatitis Prevention and Control. Screening and surveillance for hepatocellular carcinoma in patients with chronic hepatitis B virus infection [J]. Journal of Practical Hepatology, 2021, 24(6): 776-785.
[13]	Xu Zhengheng, Huang Yong, Ke Haixia, et al. Correlation of peripheral blood mononuclear cell galectin-3 levels in patients with chronic hepatitis B receiving interferon-α therapy [J]. Journal of Practical Hepatology, 2021, 24(6): 811-814.
[14]	Jiang Hao, Zhang Wen, Chen Xia. Peginterferon-α and ribavirin combination in treatment of patients with chronic hepatitis C and its impact on resting energy expenditure and nutritional status [J]. Journal of Practical Hepatology, 2021, 24(6): 815-818.
[15]	Huang Feihu, Xue Jianya, Zhu Yongmei, et al. Short-term efficacy of sofosbuvir and velpatasvir in the treatment of patients with hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(6): 819-822.